Table 2 Multivariate analysis of the association of CRPC progression with DM, HT, statin use and initial PSA levels in nonmetastatic PC patients using the Cox proportional hazard model. Patients were separated into three groups according to complications of DM and HT, or prescription of statins, i.e. (1) patients who had preexisting DM (preDM), HT (preHT) or statin use (preStatin) before the initial PC diagnosis, (2) ones newly developed DM (postDM) or HT (postHT), or started statin use (postStatin) following the onset of ADT, and (3) ones who had no DM or HT, and no statin prescription throughout the observation period, i.e. nonDM, nonHT and nonStatin, respectively. They were also categorized into two groups according to the initial PSA levels, i.e. ≥ or < 13.5 (median). HR, hazard ratio; CI, confidence interval.

From: Opposing impact of hypertension/diabetes following hormone therapy initiation and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter study